^
    23h
    Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, City of Hope Medical Center
    New P1 trial
    |
    doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • daunorubicin • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    24h
    Simultaneous chromatographic quantification of upadacitinib, nilotinib, and tryptophan decoding myeloid leukemia and liver cancer integrated with ELISA and Flow cytometry. (PubMed, J Chromatogr B Analyt Technol Biomed Life Sci)
    Fluorescence-based determination using flow cytometry with ELISA revealed a pioneer significant pro-apoptotic effect of Upadacitinib in HCC cells via modulation of the Bax/Bcl-2 axis with combination therapy showing superior anticancer effect compared to standard chemotherapy of Doxorubicin (DOX). Sustainability evaluation using AGREE (greenness) and BAGI (blueness) with RGB12 algorithm (whiteness) and spider-diagram visualization, in addition to the recently launched Multi-Color Assessment (MA) tool to confirm the method's multidimensional eco-efficiency in strong alignment with the United Nations Sustainable Development Goals (SDGs). This study further harnesses the Need-Quality-Sustainability (NQS) index and Koel's pyramid principles for holistic evaluation and benchmarking against reported approaches toward sustainable analytical oncology with personalized medicine.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    doxorubicin hydrochloride • Tasigna (nilotinib)
    2d
    Inflammatory mediators differentially regulate megakaryopoiesis and thrombopoiesis in myelofibrosis and essential thrombocythemia. (PubMed, Sci Rep)
    MF plasma increased megakaryocyte output, which was attenuated in sequential samples from ruxolitinib-treated patients...Elevated levels of circulating RANTES correlated with ET plasma-induced proplatelet formation, which was partially reverted by RANTES receptor CCR5 antagonist Maraviroc, indicating RANTES is involved in this process. These findings indicate that, in addition to clonal mutations, extrinsic inflammatory mediators play a direct role in MF and ET megakaryocyte abnormalities. The distinct cytokine profile could potentially be useful for the development of targeted therapies.
    Journal
    |
    IL6 (Interleukin 6) • BCL2L1 (BCL2-like 1) • JAK1 (Janus Kinase 1) • CD34 (CD34 molecule) • IL1B (Interleukin 1, beta)
    |
    Jakafi (ruxolitinib) • Selzentry (maraviroc)
    2d
    JADORE-BARI: Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica (clinicaltrials.gov)
    P3, N=140, Not yet recruiting, University Hospital, Brest
    New P3 trial
    3d
    Cucurbitacin I induces immunogenic cell death and synergistically potentiates cisplatin efficacy in epithelial ovarian cancer. (PubMed, Phytomedicine)
    CuI is a novel ICD inducer that elicits caspase-3/GSDME-mediated pyroptosis and boosts antitumor immunity in EOC. Notably, it enhances the chemosensitivity of EOC to CDDP, offering a promising strategy for EOC treatment.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CASP3 (Caspase 3) • HMGB1 (High Mobility Group Box 1) • CALR (Calreticulin) • ANXA5 (Annexin A5) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule) • GSDME (Gasdermin E)
    |
    cisplatin • cucurbitacin I (JSI-124)
    4d
    IKBKE modulates autophagy and progestin resistance in endometrial cancer. (PubMed, Front Oncol)
    A progestin-resistant EC cell line was established to assess the effects of IKBKE knockdown and treatment with CYT387, a selective IKBKE inhibitor...These findings highlight the crucial role of IKBKE in regulating autophagy and mediating progestin resistance in EC. This study provides new insights into IKBKE as a potential molecular target that contributes to understanding the mechanisms underlying progestin resistance in endometrial cancer.
    Journal
    |
    IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon)
    |
    Ojjaara (momelotinib)
    4d
    Fostamatinib (R788), a spleen tyrosine kinase inhibitor, sensitizes pancreatic cancer cells to oncolytic vesicular stomatitis virus. (PubMed, Mol Ther Oncol)
    Additionally, fostamatinib inhibited PDAC cell proliferation even in the absence of viral infection, while ruxolitinib did not. Our data suggest that fostamatinib may be repurposed as an effective drug that enhances OV therapy in PDAC by promoting OV replication and suppressing tumor growth.
    Journal
    |
    SYK (Spleen tyrosine kinase)
    |
    Jakafi (ruxolitinib) • Tavalisse (fostamatinib)
    4d
    A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) (clinicaltrials.gov)
    P2, N=78, Active, not recruiting, Swedish Orphan Biovitrum | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Vonjo (pacritinib)
    4d
    Momelotinib in VEXAS Syndrome (clinicaltrials.gov)
    P2, N=57, Recruiting, Groupe Francophone des Myelodysplasies | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Ojjaara (momelotinib)
    6d
    Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=39, Recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Oct 2029 --> Jan 2030 | Trial primary completion date: Oct 2027 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    Xtandi (enzalutamide) • Jakafi (ruxolitinib)
    6d
    Omics and artificial intelligence integration for stratifying blast crisis CML using COSMIC signatures and pan-cancer precision drug repurposing. (PubMed, World J Clin Oncol)
    This WES-AI-ML framework provides mutation-guided therapies for BC-CML, enabling real-time stratification and Food and Drug Administration-approved drug repurposing. While this exploratory study is limited by its small sample size (n = 7), it establishes a methodological framework for precision oncology stratification that warrants validation in larger, multi-center cohorts.
    Journal • Tumor mutational burden • BRCA Biomarker • PARP Biomarker • Pan tumor
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • BCR (BCR Activator Of RhoGEF And GTPase) • CSF3R (Colony Stimulating Factor 3 Receptor)
    |
    Lynparza (olaparib) • Jakafi (ruxolitinib) • Tibsovo (ivosidenib)
    9d
    BOOSTERS: Biologics in Folliculitis Decalvans : an Adaptative Trial Research (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
    New P2 trial